Parkinson’s disease researchers at Vanderbilt University have gotten the go-ahead from the U.S. Food and Drug Administration to expand a trial of a new treatment using deep brain stimulation.
The phase III trial will recruit 350 patients at 15 academic medical centers in the United States and Europe, according to a press release issued Friday by Vanderbilt University Medical Center.
“This research has been decades in the making, and we are so excited to receive this approval to expand the trial,” said Dr. David Charles, the chief medical officer of the Vanderbilt Neuroscience Institute. “Our hypothesis is that patients who have deep brain stimulation applied in the very early stage of Parkinson’s disease will do much better in quality of life and motor function and have delayed onset of disability and medication-associated complications. Expanding the trial will help test that hypothesis.”
Parkinson’s disease is believed to affect as many as 7 million people worldwide, according to the press release.
To learn more about the trial, contact Vanderbilt University Medical Center at 615-343-2961.
Reach Tom Wilemon at 615-726-5961 and on Twitter @TomWilemon.